Discloseable transaction subscriptions for wealth management products
Filed with HKEX · Stock code 6990 · · 8 pages · English
Summary by 6ix AI
This filing is a discloseable transaction announcement regarding subscriptions for wealth management products by Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.. The company has entered into structured deposit agreements with China Zheshang Bank and Bank of China, involving significant principal amounts. The subscriptions are expected to generate higher returns than traditional bank deposits, utilizing the company's idle funds. The transactions are subject to reporting requirements under the Listing Rules due to their size relative to the company's financials.
Written by 6ix AI from the company’s filing. How 6ix writes summaries
Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. on 6ix
Earlier from Sichuan Kelun-Biotech Biopharmaceutical
- Monthly Return of Equity Issuer on Movements in Securities for the month ended 31 October 2026
- Voluntary announcement new indication application for core product TROP2 ADC sacituzumab tirumotecan (sac-TMT) accepted by the national medical products administration
- Voluntary announcement results from multiple studies of innovative drugs at 2026 ESMO congress
- Monthly Return of Equity Issuer on Movements in Securities for the month ended 30 September 2026
- Multiple Sacituzumab Tirumotecan (sac-TMT) Studies Selected as LBAs at ESMO 2026, OptiTROP-Lung04 and OptiTROP-Lung06 to be Presented in the Lung Cancer Session
Follow Sichuan Kelun-Biotech Biopharmaceutical into a list and get an email when it puts out news.
Follow Sichuan Kelun-Biotech Biopharmaceutical